Polpharma Strengthens Its Position in Central and Eastern Europe – Biofarm, the Leader of the Romanian Market, Joins the Group
21.7.2026 11:00:00 CEST | news aktuell GmbH | Press Release
Warsaw, 21.07.2026 - Polpharma Group has completed the acquisition of the Romanian pharmaceutical company Biofarm. The transaction is a clear step in the execution of the Group’s growth strategy and strengthens its position in Central and Eastern Europe. With Biofarm joining the Group, Polpharma is expanding the scale of its operations, reinforcing its presence in key regional markets, and creating new opportunities to improve patients’ access to trusted medicines across the region and beyond.

“Poland remains the place from which we define the strategic direction of our Group and pursue our ambitious international growth plans. The acquisition of Biofarm confirms our long-term commitment to building a strong, multiregional pharmaceutical organization. We are a privately owned company with an entrepreneurial gene: we act responsibly, move with speed, and believe in cooperation. This is how we want to grow — always with patients’ needs at the center and with a tangible contribution to improving access to medicines and strengthening pharmaceutical security across Central and Eastern Europe,” says Sebastian Szymanek, CEO of Polpharma Group.
Combining the strengths of both organizations creates greater opportunities to develop and provide patients with access to a broader portfolio of trusted products. Biofarm’s strong position in Romania and Polpharma’s regional footprint create a platform to support the continued availability of Biofarm products in Romania, while also opening potential for their presence in additional markets.
Biofarm is one of the most recognized pharmaceutical manufacturers in Romania. The company has operated continuously since 1921, owns two manufacturing facilities, and exports its products to countries across Europe and Asia. Its portfolio includes more than 200 products spanning dozens of therapeutic areas.
“Joining Polpharma Group opens up new opportunities for Biofarm’s future development. By combining the experience of our local team, deep market knowledge, and the strength of the Group, we will be able to develop our product portfolio even more effectively, explore opportunities for Biofarm products in other markets, and create greater value for patients and business partners,” says Tamás Uri, General Manager, CEE Region at Polpharma Group.
In the coming phases, the Group will focus on leveraging the synergies resulting from the combination of competencies, product portfolios, and the experience of both organizations.
Contacts
Grażyna Stachowska
Tel:+48 885 610 273grazyna.stachowska@polpharma.comImages
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
The Quality Group grows H1 revenue by more than 40% to over €850 million21.7.2026 10:04:58 CEST | Press Release
H1 2026 revenue reached €850 million – up more than 40% versus H1 2025 Demand continues to grow as more consumers seek better nutrition, health and performance solutions Company growth is broad-based, reflecting successful execution of strategies across brands, product categories, channels, and markets
Battery electric vehicle prices fell 18% and model choice quadrupled between 2020 and 202520.7.2026 06:00:00 CEST | Press Release
New study analyzes EV purchase prices and market trends in Germany, Europe's largest car market
Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich16.7.2026 10:32:18 CEST | Press Release
Aachen, Germany, 16 July 2026 – Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic acid therapeutics into innovative treatments that can make a meaningful difference for patients. Joining the CNATM provides Grünenthal with a valuable platform to strengthen its oligonucleotide drug discovery capabilities and connect its growing internal expertise with one of Germany’s leading academic and biotech innovation ecosystems. Over the last few years, Grünenthal has built strategic in-house capabilities to advance oligonucleotide modalities, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA), as potential therapeutic approaches for pain and related neurological indications. One of Grünenthal’s key objectives for the collaboration
“Wheel of Watt”: PLAN-B NET ZERO launches prize draw with instant prizes and a €1,000,000 top prize15.7.2026 12:45:34 CEST | Press Release
Three prize tiers, one big goal: from 15 July 2026, the digital energy supplier specialising in renewable energy is giving away instant prizes, monthly non-cash prizes and a top prize of €1,000,000. The full terms and conditions of participation set out all the details.
They’re really going for it: emporia launches the first 5G smartphone with a screen warranty15.7.2026 08:30:00 CEST | Press Release
Better safe than sorry: the emporiaSMART.8 with Smartcover and rubber protectors
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
